A new study suggests that a simple urine test could dramatically improve bladder cancer diagnosis and patient care. The research highlights noninvasive screening tools that may reduce reliance on uncomfortable and costly procedures.
Researchers discovered that analyzing patterns of cell-free DNA (cfDNA) fragments in urine can accurately detect bladder cancer and assess its stage. Published in The Journal of Molecular Diagnostics by Elsevier, the study indicates this method could reduce the need for repeated cystoscopies, lower medical costs, and enhance patient comfort.
Bladder cancer is both common and prone to recurrence, making it difficult to manage. Current diagnostic methods remain largely invasive and expensive. Cystoscopy, which involves inserting a thin tube through the urethra, is standard, while urine cytology, a noninvasive test, suffers from limited sensitivity.
Urine cfDNA as a Diagnostic Tool
The research team analyzed urine samples from 156 bladder cancer patients and 79 healthy controls. Using real-time PCR, they measured both the quantity and size distribution of cfDNA fragments from five genes: ACTB, AR, MYC, BCAS1, and STOX1.
“Our most significant finding was that the small fragment of the MYC gene may be a powerful diagnostic tool,” said lead investigator Pilar Medina, PhD, of the Health Research Institute Hospital La Fe (IIS La Fe) in Valencia, Spain. “It showed 97% specificity and 88% predictive value for detecting muscle-invasive bladder cancer.”
MYC encodes a transcription factor essential for regulating cell growth, proliferation, and metabolism.
Biomarkers for Staging and Relapse
The study also found that the ratio of large to small fragments of the ACTB gene and the small fragment of the AR gene correlated with disease severity, suggesting these could serve as staging biomarkers. Gene integrity may also help detect cancer relapse.
Lead author Raquel Herranz, MS, of IIS La Fe, said, “With the rise of liquid biopsies and personalized medicine, our study provides a practical, noninvasive alternative to traditional diagnostics. This is among the first studies to assess urine cfDNA fragmentation across most bladder cancer stages.”
Dr. Medina added, “Our findings show that urine contains far more diagnostic information than previously realized. This approach could revolutionize how we detect and manage bladder cancer, improving both patient comfort and clinical outcomes.”
Related topic：
